Assertio Therapeutics, Inc. kohta
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
Peakontor251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Asutatud2018
StaatusAktiivne
Patendid1 patent
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
Arvustused
Arvustusi pole veel. Töötanud ettevõttega Assertio Therapeutics, Inc.? Olge esimene, kes oma kogemust jagab.
Õiguslik teave
| Juriidiline nimi | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20Vaata saidil GLEIF ↗ |
| Registreeritud aadress | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| Staatus | Aktiivne |
Allikad: GLEIF · uuendatud 16. Oktoober 2026
Kontakt ja lingid
Asukoht
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Kas see on teie ettevõte?
Taotlege seda lehte tasuta, et lisada logo, tooted, fotod ja töökohad ning vastata arvustustele.
Taotle seda lehteLiitu Heelkyga, et luua ühendusi, palgata ja kasvada
Looge tasuta konto, et inimestele kirjutada, töökohtadele kandideerida ja missioone avaldada.
Liitu kohe — see on tasuta